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Background: Treatment adherence is critical for the success of antiretroviral therapy (ART) 
for people living with HIV. There is limited representative information on ART drug adherence 
and its associated factors from Southern Ethiopia. We aimed at estimating the level of adherence 
to ART among people living with HIV and factors associated with it in 20 randomly selected 
ART clinics of Southern Ethiopia.
Methods: In this cross-sectional study, we interviewed consecutive HIV patients on first-line 
antiretroviral regimen attending the clinics in June 2014 using a pretested and structured 
questionnaire. For measuring adherence, we used 4-day recall method based on “The AIDS 
Clinical Trial Group adherence assessment tool”. Patients were classified as “Incomplete 
adherence” if they missed any of the doses in the last 4 days. Data were singly entered using 
EpiData and descriptive analysis, and unadjusted odds ratios were calculated using EpiDataStat 
software. Multivariate logistic regression analysis was performed using Stata v12.0.
Results: Of 974 patients interviewed, 539 (56%) were females, and mean age was 35 years. 
The proportion of patients with incomplete adherence was 13% (95% confidence interval: 
11%–15%). In multivariate analysis, factors significantly associated with incomplete adherence 
included young age, being Protestant Christian, consuming alcohol, being single, and being a 
member of an HIV association. Psychosocial factors like stigma, depression, and satisfaction 
to care were not associated with incomplete adherence in the current context.
Conclusion: The overall adherence to ART was good. However, there were certain subgroups 
with incomplete adherence who need special attention. The health care providers (especially 
counselors) need to be aware of these subgroups and tailor their counseling to improve adherence 
among these groups. Exploratory qualitative studies may help uncover the exact reasons for 
incomplete adherence.
Keywords: operational research, SORT IT, treatment compliance
Background
Globally, there were an estimated 12.9 million people living with HIV on antiretroviral 
therapy (ART) in 2013, and of these, 9.1 million (71%) were in Africa.1 Access to ART 
has expanded significantly in the last decade and has saved hundreds of thousands 
of lives. The impact of ART on HIV disease progression and transmission depends 
on many factors, one of which is adherence to ART. Adherence assessment has 
been included as one of the five early warning indicators for HIV drug resistance in 
countries scaling up ART program.2 Studies on the benefits of treatment adherence 
have found that more than 95% adherence is required for effective and sustained viral 
suppression.3,4 Systematic reviews have reported that adherence to ART ranged from 
55% (95% CI [confidence interval]: 49%–62%) in developed countries to 77% (95% 
CI: 68%–85%) in developing countries. This indicates better adherence in developing 
countries than developed ones.5 Use of fixed dose combinations,3 as well as factors 
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such as sex, depression, social support, pill burden, payment 
for drugs, adverse drug effects, malnutrition have been shown 
influence the adherence.5,6
In Ethiopia, HIV/AIDS has been and still is a big challenge 
to the health system, as elsewhere in most sub-Saharan African 
countries. With an estimated HIV prevalence of 1.2% (95% 
CI: 1.1%–1.4%), HIV/AIDS is one of the major causes 
of deaths.7 Previous studies from Ethiopia have reported 
ART adherence levels ranging from 73% to 96%.6,8–11 
Most of these were conducted in urban areas, had small 
sample size, were limited to one or two facilities, and were 
mostly reported from Northern Ethiopia. There is limited 
representative information from Southern Ethiopia. While 
each study focused on selected factors affecting adherence, 
no single study examined all the factors (like demographic, 
behavioral and clinical characteristics, social support, access 
to health facilities, depression, stigma, and knowledge on 
ART) comprehensively together. Therefore, we aimed at 
determining the level of adherence to first-line ART among 
HIV infected patients enrolled into HIV care in Southern 
Ethiopia and to identify various factors associated with 
adherence to first-line ART.
Methods
study design
This was a cross-sectional study involving a structured 
interview of HIV patients attending ART clinics (exit 
interview).
study setting
Ethiopia is located in East Africa (population: 88 million) 
and is divided into eleven administrative regions. Southern 
Nations, Nationalities and Peoples’ Regional State 
(SNNPRS), with an estimated population of 16.5 million, is 
the third largest region and represents approximately 20% of 
the country’s population. Approximately 93% of the popula-
tions in SNNPRS live in rural areas.12 The prevalence of HIV 
infection among adults in the region was 0.9%, lower than 
the national average.7
In 2014, there were a total of 22 public hospitals, 448 
public health centers, and 3,340 health posts in SNNPRS. The 
potential health service coverage, defined as population living 
within 10 km of a primary heath care unit in 2010, is estimated 
to be 93%. In total, 22 hospitals and 141 health centers were 
providing ART care in the region. Most HIV-infected patients 
receive care from government health facilities.13
The National HIV programme has a vertical structure, 
and all ART clinics are staffed by trained and certified health 
workers. The national guidelines for starting ART including 
the use of prophylactic medications like cotrimoxazole 
preventive therapy and isoniazid preventive therapy are based 
on WHO (World Health Organization) 2010 guidelines.14
Patients are started on first-line ART regimen consisting 
of (tenofovir or zidovudine)/lamivudine/(nevirapine or 
efavirenz) twice a day or once a day depending on the regimen. 
Patients receiving ART are expected to attend the ART clinic 
monthly for the first 3–6 months and once in 2 months after 
that (once assessed as clinically stable). All patients are 
counseled about the benefits of adherence to treatment and 
other behavioral modifications during their routine visits to 
the ART centers by the adherence counselors.15 ART and all 
laboratory investigations are provided free of cost to patients 
at all health facilities.
study population
All consecutive HIV-infected adults aged 15 years and above 
registered for ART in selected health facilities and attending 
the ART clinic in June 2014. In total, 12 hospitals and 8 heath 
centers providing ART services were randomly selected 
using random number generator on Excel. We included 
only HIV-infected adults on first-line ART regimen in these 
selected facilities.
Definition of adherence
We used 4-day recall method for measuring adherence. 
Patients were asked whether they had taken their medications 
each day during the past 4 days. If none of the doses was missed 
during the past 4 days, adherence was considered “complete”. 
Patients were classified as “Incomplete adherence” if they 
missed any of the doses in the 4 days period.
Several methods including patient self-reporting, pill 
counts, audits of pharmacy refill records, drug level mea-
surements in blood, and viral load testing have been tried to 
measure adherence. Each method has its own advantages and 
challenges.16 Drug level measurements are expensive and can-
not be used in routine programmatic settings. Access to viral 
load measurements is not yet a reality in Ethiopia. Studies using 
self-reported adherence have been documented to correlate 
with viral load.17 Different periods of recall, ranging from 2 to 
365 days (mode =7 days), have been used in previous studies.17 
The AIDS Clinical Trials Group adherence instrument uses a 
4-day recall period and has been shown to correlate well with 
viral load.18 Other studies have also shown that brief self-report 
measures of antiretroviral adherence can be robust in measur-
ing adherence to treatment.17 Since the duration of recall is less, 
we used this method to minimize recall limitation.
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Data variables and data collection
Variables included age, sex, education, marital status, place 
of residence, alcohol use, type of treatment regimen and 
frequency of dosing, assistance to remember medication, 
perceived stigma, level of depression, knowledge on ART, 
satisfaction about care, and adherence to ART. We adapted 
“the Berger HIV Stigma Scale”19 for assessing stigma related 
to HIV/AIDS. Depression was assessed using a modified 
version of Beck Depression Inventory.20
Interviews with study participants were conducted at 
ART clinics by comprehensive HIV-care-trained and certified 
health workers. The selected data collectors were provided 
3 days training, including class sessions and pretesting 
the data collection formats. To avoid socially desirable 
responses, the patients were interviewed by health workers 
working in a different health facility.
Analysis and statistics
Data were singly entered and analyzed using EpiData 
software (version 3.1 for data entry and version 2.2.2.182 
for analysis; EpiData association, Odense, Denmark). 
Incomplete adherence to ART was expressed as proportion 
with 95% CI. Unadjusted odds ratios were calculated to 
assess possible association between incomplete adherence 
and the independent variables. Variables significant at 
P-value of less than 0.2 in unadjusted analysis were 
included in multivariate analysis. Adjusted odds ratios using 
multivariate logistic regression were calculated to assess the 
independent effect of factors on incomplete adherence, and 
a P-value of less than 0.05 was considered statistically sig-
nificant. The multivariate regression analysis was performed 
using Stata v12.0 (Stata Corporation, Release 12, College 
Station, TX, USA).
ethics
Permission to carry out the study was obtained from SNNPR 
Health Bureau. Local ethics approval was obtained from the 
Institutional Review Board of the SNNPR Health Bureau. 
The study was also approved by the Ethics Advisory Group 
of the International Union Against Tuberculosis and Lung 
Disease, Paris, France. Informed consent for the study was 
obtained from all participants.
Results
A total of 1,263 patients were interviewed during the study 
period. Complete information was available for 974 (77%) 
patients, and these were included in the final analysis. Of 289 
patients excluded, information on age and sex was available 
for 77 patients, and there was no difference in distribution 
compared to those included in the analysis.
Sociodemographic and behavioral characteristics of 
HIV-infected patients on ART are shown in Table 1. The mean 
age (standard deviation) of the participants was 35 (9) years, 
and 539 (55.5%) were females. Most participants (61.2%) 
had no formal education. Fifteen percent of the participants 
reported that they consumed alcohol in the past 1 month.
Health facility access, social support, and treatment 
characteristics are described in Table 2. Fifty-two percent of 
the patients reached ART clinic within 30 minutes by walk, 
and little more than half used vehicles. Majority (86.2%) of 
them were on ART for more than a year, and approximately 
two-thirds were on a treatment regimen that requires taking 
the drugs twice a day.
Table 1 sociodemographic and behavioral characteristics of 
hiV-infected patients on ArT and their association with treatment 







Total 974 122 (12.5) –
Age in years (n=931)
15–24 59 8 (13.6) 2.7 (0.9, 7.4)
25–34 382 50 (13.1) 2.5 (1.2, 5.5)*
35–44 347 45 (13.0) 2.5 (1.2, 5.5)*
$45 143 8 (5.6) ref
sex (n=972)
Male 433 49 (11.3) ref
Female 539 73 (13.5) 1.2 (0.8, 1.8)
Place of residence (n=958)
Urban 774 95 (12.3) ref
rural 184 25 (13.6) 1.1 (0.7, 1.8)
educational status (n=969)
no formal education 593 65 (11.0) ref
Formal education 376 57 (15.2) 1.5 (1.0, 2.1)
Marital status (n=974)
currently single 243 36 (14.8) 1.6 (1.03, 2.6)*
currently married 546 53 (9.7) ref
not recorded 185 33 (17.8) 2.02 (1.3, 3.2)*
religion (n=972)
Protestant christian 367 65 (17.7) 2.8 (1.3, 6.0)*
non-Protestant
christiana
494 48 (9.7) 1.4 (0.6, 3.0)
Muslim 111 8 (7.2) ref
current alcohol use (n=966)
Yes 141 27 (19.1) 1.8 (1.2, 3.0)*
no 825 94 (11.4) ref
chat chewing (n=931)
current use 45 9 (20.0) 1.8 (0.8, 3.8)
Past use 106 15 (14.2) 1.2 (0.7, 2.1)
never use 780 96 (12.3) ref
Notes: aIncludes Orthodox and Catholic Christians; *statistically significant.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; n, number; 
Or, odds ratio; ref, reference category.





Psychosocial characteristics and level of knowledge 
of HIV-infected patients on ART are described in Table 3. 
Forty-nine percent of the study participants had expressed 
experience of stigma due to their disease status. Only 25% 
had complete knowledge on ART.
The proportion of patients with incomplete adherence was 
13% (95% CI: 11%–15%). Of them, 68%, 16%, and 16% 
missed one, two, and three or more doses, respectively. Age 
group 25–44 years, currently single, Protestant Christian, 
alcohol use in the past 1 month, and being a member of the 
HIV/AIDS association were associated with incomplete 
adherence in unadjusted analysis (Tables 1–3). In multivari-
ate analysis, being in the age group 25–44 years, being a 
Protestant Christian, being a member of HIV/AIDS associa-
tion, consuming alcohol, and being single were associated 
with incomplete adherence (Table 4).
Discussion
This study, involving a large number of health facilities from 
the southern region of Ethiopia, showed that a majority of 
the patients were adherent to the ART medications. Factors 
associated with incomplete adherence were young age, being 
a Protestant Christian, membership in HIV/AIDS association, 
alcohol consumption, and being single.
Table 2 health facility access, social support, and treatment 
characteristics of hiV-infected patients on ArT and their 
association with treatment adherence in selected health facilities 







Time to reach health facility (n=942)
,30 minutes 493 60 (12.2) ref
$30 minutes 458 58 (12.7) 1.1 (0.7, 1.5)
Means of transport (n=960)
Walking or animal 423 48 (11.3) ref
Vehicle 537 71 (13.2) 1.2 (0.7, 1.8)
Assistance to remember medication (n=940)
Yes 701 89 (12.7) 1.0 (0.7, 1.6)
no 239 30 (12.6) ref
Membership in any hiV association (n=961)
Yes 222 41 (18.5) 1.8 (1.2, 2.8)*
no 739 81 (11.0) ref
Treatment duration, months
#12 132 12 (9.1) ref
13–48 384 46 (12.0) 1.4 (0.7, 2.7)
$48 443 64 (14.4) 1.7 (0.9, 3.2)
Treatment regimen
AZT based 434 54 (12.4) ref
TDF based 464 61 (13.1) 1.1 (0.7, 1.6)
Others 76 7 (9.2) 0.7 (0.3, 1.6)
Treatment dose per day
Twice daily 607 69 (11.4) ref
Once daily 367 53 (14.4) 1.3 (0.9, 1.9)
Note: *Statistically significant.
Abbreviations: ART, antiretroviral therapy; AZT, zidovudine; CI, confidence interval; 
Or, odds ratio; ref, reference category; TDF, tenofovir.
Table 3 Psychosocial characteristics and level of knowledge of 
hiV-infected patients on ArT and their association with treatment 









Yes 477 54 (11.3) ref
no 466 64 (13.7) 1.3 (0.9, 1.8)
Depression (n=921)
no or minor depression 252 39 (15.5) 2.0 (0.9, 4.7)
low depression 585 70 (12.0) 1.5 (0.7, 3.4)
high depression 84 7 (8.3) ref
satisfaction to care (n=956)
Not satisfied or neutral 125 15 (12.0) ref
Satisfied 831 105 (12.6) 1.1 (0.6, 1.9)
ArT knowledge (n=954)
incomplete knowledge 716 87 (12.2) ref
complete knowledge 238 32 (13.4) 1.1 (0.7, 1.7)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; n, number; 
Or, odds ratio; ref, reference category.
Table 4 Multivariate logistic regression analysis of factors 
associated with incomplete treatment adherence among hiV-
infected patients on ArT in selected health facilities in southern 
ethiopia, June 2014
Variables AOR (95% CI)
Age in years
15–24 2.1 (0.7, 6.3)
25–34 2.3 (1.1, 5.1)*
35–44 2.2 (1.1, 5.0)*
$45 ref
educational status
no formal education ref
Formal education 1.4 (1.0, 2.2)
religion 
Protestant christian 3.1 (1.4, 4.1)*
non-Protestant christiana 1.5 (0.7, 3.3)
Muslim ref
Membership in any hiV association
Yes 1.8 (1.2, 2.8)*
no ref
Alcohol drinking
Yes 1.9 (1.2, 3.2)*
no ref
Marital status
currently single 1.7 (1.03, 2.7)*
currently married ref
Unknown 1.9 (1.2, 3.2)*
Treatment dose
Once per day 1.4 (0.9, 2.0)
Twice per day ref
Notes: aIncludes Orthodox and Catholic Christians; *statistically significant.
Abbreviations: ART, antiretroviral therapy; AOR, adjusted OR; CI, confidence 
interval; Or, odds ratio; ref, reference category.




Adherence to antiretroviral therapy in southern ethiopia
Our study findings on adherence levels are comparable 
with other studies from Ethiopia.21,22 A recent study from 
Northern Ethiopia reported adherence of 96% among 
HIV-infected patients on ART, higher than this study.23 
The difference might be due to the use of a 30-day recall 
method for measuring adherence; also the sample popula-
tion was only from referral hospitals in the previous study. 
WHO recommends that adherence to ART less than 90% 
among HIV-infected persons is an early warning indica-
tor for monitoring emergence and transmission of HIV 
drug resistance.2 However, studies conducted using newer 
NNRTI (nonnucleoside reverse transcriptase inhibitor) 
regimens (eg, rilpivirine, etravirine), though unavailable 
in the current setting, indicated adherence level as low as 
85% could achieve successful viral suppression.24 This 
study with adherence levels marginally less than 90% 
without newer nonnucleoside reverse transcriptase inhibitor 
calls for measures to improve adherence to prevent drug 
resistance.
In our study, relatively younger age (25–44 years) indi-
viduals were more nonadherent to treatment compared with 
older age group (more than 44 years). Exact reasons for poor 
adherence were not explored. Previous studies have reported 
reasons for poor adherence among young people, includ-
ing denial and fear of HIV infection, low self-esteem, and 
unstructured and chaotic life styles.25–27 Also, a few studies 
have documented high levels of risky sexual behavior among 
young age groups on ART.28,29 Poor adherence to ART and 
high-risk sexual behavior among young individuals may 
increase the spread of drug resistant HIV viruses. Incomplete 
treatment adherence may also affect future drug choice for 
such patients for managing treatment failure. The health 
system should recognize such complex needs of the young 
age group to design a targeted counseling and support for 
this high-risk group.
Regarding the association between marital status and 
adherence, the findings were not consistent across the 
studies.30 In our study, we found an increased risk of 
incomplete adherence among individuals who were single 
or not married. Surprisingly, being member of an HIV 
association was associated with incomplete adherence to 
treatment. This might have happened because patients with 
poor adherence were usually advised to be part of such 
association and this study, being a cross-sectional one, could 
not establish temporal relations between the two variables.
Studies have reported a statistically significant association 
between religion and antiretroviral drug adherence.31–35 Our 
study showed that Protestant Christians were more likely 
to be nonadherent compared to other religions. Qualitative 
studies may help in finding the contextual reasons behind 
this difference.
Similar to other studies, alcohol use was associated 
with incomplete adherence. Previous literature showed that 
alcohol interacts with ART treatment through both behavioral 
and physiological pathways. Behaviorally, alcohol use is 
linked to risky sexual behavior, apart from the poor adherence 
observed in our study.36
We did not find association between psychosocial factors 
like perceived stigma and depression and knowledge on 
ART with adherence. Literature reviews also indicated 
inconsistent findings on the association between these 
variables, though most publications tend to show the presence 
of associations.37–40
There are few implications for the HIV program. First, 
the health care providers, especially counselors, should 
be informed about the high-risk groups for incomplete 
adherence and appropriately trained to guide these patients. 
During routine counseling sessions, they can recognize/
identify the high-risk groups and provide focused counseling 
after exploring the barriers to adherence. Second, existing 
support systems, like associations for HIV patients, can be 
strengthened. Innovative approaches like creating medication 
adherence clubs and mobile phone reminders for the selected 
high-risk groups can be tried to improve adherence. Third, 
involving the community leaders, especially religious 
leaders, may help to reduce this problem.
This study has several strengths. First, the study had 
a large sample size involving patients from several health 
facilities. Second, the recall period was shorter than similar 
studies in Ethiopia, minimizing recall bias, and data 
collection by a trained health worker from a different health 
facility may have reduced potential social desirability bias. 
Third, we comprehensively assessed the factors associated 
with incomplete adherence including psychosocial and 
health access factors. There are also a few limitations. The 
cross-sectional nature of the design does not allow us to 
establish true cause–effect relations. Furthermore, the level of 
adherence may be an overestimate because of self-reporting, 
and we could not validate it using other methods like viral load 
testing. The response rate in our study is 77%, though those 
excluded were similar in age and sex distribution. The reasons 
for providing incomplete questionnaire responses could be 
withdrawal from the interview after consenting to participate 
in the study and workload from data collectors, among others. 
This might still have resulted in over- or underestimation 
of overall level of adherence.





In conclusion, around nine out of ten patients on ART 
adhered to the medication. However, there were certain 
subgroups with incomplete adherence. Innovative approaches 
including mobile phone reminders and forming medication 
adherence clubs could be tried to help improve adherence 
for patients with the identified risk factors.
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